



This is a repository copy of *Themes that Determine Quality of Life in Patients with Peripheral Arterial Disease: A Systematic Review*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/131735/>

Version: Accepted Version

Article:

Aber, A. orcid.org/0000-0002-5707-2430, Lumley, E., Phillips, P. orcid.org/0000-0003-0241-1527 et al. (3 more authors) (2018) Themes that Determine Quality of Life in Patients with Peripheral Arterial Disease: A Systematic Review. *The Patient - Patient-Centered Outcomes Research*, 11 (5). pp. 489-502. ISSN 1178-1653

<https://doi.org/10.1007/s40271-018-0307-7>

This is a post-peer-review, pre-copyedit version of an article published in *The Patient*. The final authenticated version is available online at: <https://doi.org/10.1007/s40271-018-0307-7>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 1) Themes that Determine Quality of Life in Patients with Peripheral Arterial Disease: a
2 systematic review.

3 2) Authors: Ahmed Aber^a, Elizabeth Lumley^a, Patrick Phillips^a, Helen Buckley Woods^a, ,
4 Georgina Jones^{ab}, Jonathan Michaels^a

5

6 Ahmed Aber, University of Sheffield, a.aber@sheffield.ac.uk

7 Elizabeth Lumley, University of Sheffield, e.lumley@sheffield.ac.uk

8 Patrick Phillips, University of Sheffield, p.phillips@sheffield.ac.uk

9 Helen Buckley Woods, University of Sheffield, h.b.woods@sheffield.ac.uk

10 Georgina Jones, Leeds Beckett University, g.l.jones@leedsbeckett.ac.uk

11 Jonathan Michaels, University of Sheffield, j.michaels@sheffield.ac.uk

12

13 3) ^aInstitution: School of Health and Related Research, University of Sheffield, Sheffield

14 4) ^bInstitution: School of Social Sciences, Leeds Beckett University, Leeds

15 5) *Corresponding author: Ahmed Aber, Regent Court, 30 Regent Street, School of
16 Health and Related Research, University of Sheffield, Sheffield, S1 4DA.

17 E-mail: a.aber@sheffield.ac.uk.

18 Tel: +44 (0) 114 222 4029

19 Fax: +44 (0) 114 222 0740

20

21 6) Source of funding for research and publication: This review presents independent
22 research funded by the National Institute for Health Research (NIHR) under the Programme
23 Grants for Applied Research programme (RP-PG-1210-12009). The views expressed are
24 those of the authors and not necessarily those of the NHS, the NIHR or the Department of
25 Health.

26

27

28

29

30

31

32

33

34 Abstract

35

36 **Objectives:** The aim of this study was to identify domains that determine quality of life in patients with
37 peripheral arterial disease (PAD) and find the patient reported outcome measures (PROMs) that can
38 examine the identified themes.

39 **Methods:** A systematic review of all the main six databases was undertaken to identify primary
40 qualitative studies reporting on PAD patients' health and/or quality of life. Quality of studies was
41 assessed using the CASP criteria. Findings from the included studies were analysed using
42 Framework Analysis methodology. The identified themes were mapped against the items/domains of
43 validated patient reported outcome measures (PROMs) used in patients with PAD.

44 **Results:**

45 The systematic review identified eight papers that fulfilled the inclusion criteria. The included papers
46 reported the views of 186 patients with PAD including patients with intermittent claudication, critical
47 ischaemia and amputation secondary to PAD.. The overall quality of the included studies was good
48 based on CASP criteria. Framework Analysis identified thirty-five themes that were divided into six
49 main groups: symptoms, impact on physical functioning, impact on social functioning, psychological
50 impact, financial impact and process of care.. The best fit generic and disease specific PROMs were
51 Nottingham health profile (NHP) and Vascular quality of life questionnaire (VascuQoL) respectively.
52 None of the PROMs covered all the themes important to patients with PAD.

53 **Discussion:**

54 The findings from the review identified the important domains that affect patients living with PAD None
55 of the current generic and disease specific PROMs provide a comprehensive measure for all themes
56 that impact the daily living of patients with PAD.

57

58

59 Key messages:

- 60 - Peripheral arterial disease is a spectrum of conditions ranging from asymptomatic disease
61 and minor claudication to limb loss.
- 62 - Understanding and measuring quality of life in these patients is of paramount importance to
63 guide intervention.
- 64 - This systematic review is the most comprehensive attempt in measuring the impact of this
65 disease in its different manifestation and can help improve current measures that are used to
66 measure quality of life.

67 **Introduction**

68

69 Population studies suggest that 1 in 5 people above the age of 60 have some degree of peripheral
70 artery disease (PAD) in the lower limbs. The incidence of this disease increases with age **(1)**. Most
71 patients with PAD are asymptomatic however patients can present with a spectrum of symptoms,
72 reflecting different stages of the disease. The most common clinical presentation is intermittent
73 claudication (IC), which is pain in the leg on walking; only 20% of these patients develop severe
74 symptoms of critical limb ischaemia (CLI) **(2)**. Patients with CLI can present with rest pain, non-
75 healing leg ulcers or gangrene; if they do not receive treatment they may lose part of their lower limbs
76 **(3,4)**. Patients with CLI have a high risk of mortality with nearly 25% dying and 30% requiring major
77 lower limb amputation within one year **(5,6)**. Symptomatic PAD results in significant functional
78 limitations and reduced health-related quality of life (HRQoL) in affected patients **(5)**.

79 PAD is a chronic disease and patients suffering with this condition need support to choose the best
80 treatment strategy to reduce the impact on their quality of life. HRQoL can be measured using either
81 generic or disease specific patient reported outcome measures (PROMs). Patient choice over
82 treatment and care is a central feature of most advanced health care systems, it is proposed that
83 information gathered by PROMs from patients directly can help inform the choice of treatments and
84 promote equity as well as excellence **(7)**.

85 Patients' experience of treatment and care is a major indicator of quality and there has been a huge
86 expansion in the development and application of PROMs. These instruments examine the most
87 important issues to the patients by asking them directly about any changes. PROMs provide an
88 insight into the way patients perceive their health and the impact that treatments have on their quality
89 of life.

90 The aim of this study was to systematically review the qualitative evidence of people's experiences of
91 living with PAD. The identified domains were then mapped against the items/domains of identified
92 validated generic and disease specific PROMs **(8)**. The intention was to find the PROMs that captured
93 the most important issues to patients with PAD.

94 **Method**

95 The review aimed to find all the primary qualitative research studies (interview and/or focus groups)
96 that explicitly investigated the impact of PAD on daily living, health and quality of life. The inclusion

97 criteria included any patients with PAD (IC, CLI, ischaemic ulceration, necrosis, gangrene and
98 amputation due to PAD). Any studies with undefined population or mixed population that included the
99 views from patients not suffering with PAD were excluded.

100 For further information regarding the inclusion and exclusion criteria refer to **table 1**.

101 This systematic review was undertaken and reported in accordance with the general principles
102 recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
103 (PRISMA) statement. In accordance with the study protocol
104 (https://www.sheffield.ac.uk/polopoly_fs/1.552397!/file/DP_16_05.pdf) (9), searches were conducted
105 from inception up to April 2017 in bibliographic databases including CINAHL via EBSCO, Medline and
106 Medline in Process via Ovid, Embase via Ovid, PsycINFO via Ovid, Social Science Citation Index/
107 Science Citation Index via Web of Science (Thomson Reuters) and Proquest dissertations and
108 theses. No language or date constraints were applied.

109 **Insert Table 1**

110

111 The search strategy combined condition terms, terms for patient views and terms for qualitative
112 studies (which augmented a qualitative study filter) (9). Further details of the search strategy are
113 provided in **Appendix 1** (supporting information).

114

115 **Study selection**

116 The search results were entered into Endnote X8™ (Thomson Reuters, Philadelphia, USA), two
117 reviewers (AA, PP) independently screened the titles for inclusion and exclusion in accordance with
118 the set criteria in the protocol. All titles were examined, and any citations that clearly did not meet the
119 inclusion criteria (for example mixed population, quantitative PROMs data, unrelated to PAD) were
120 excluded. For included titles, abstracts were read and for the included abstracts, full-text articles were
121 obtained.

122

123 **Quality assessment**

124 The Critical Appraisal Skills Program (CASP) qualitative checklist instrument was used to assess the
125 methodological quality of the included studies in the review (10). This was selected as it assesses
126 both the appropriateness and the quality of reporting of the studies included and is commonly used in

127 qualitative reviews of evidence (11). CASP consists of ten questions about the qualitative
128 methodology that are answered either as yes, no or unclear. Two of the authors (AA, EL)
129 independently examined the quality of each study and any inconsistencies were resolved by
130 discussion or involving a third author (GJ).

131

132 **Data extraction and analysis**

133 The data on authors, year of publication, country of study, number of participants, research aims,
134 methods of recruitment, method of data collection, key results and analysis were extracted and
135 tabulated for all the included studies. The first author (AA) uploaded all the papers into the qualitative
136 data analysis software NVivo10 (QSR International, Doncaster, Victoria, Australia) and the primary
137 and secondary text (patient quotes reported in the articles and themes), were analysed. Framework
138 Analysis was used to identify common and variable themes within the text of each article (12). The
139 first stage of the analysis was undertaken by reading all the included papers to identify common terms
140 and themes from within and across the articles. The second stage involved identifying a thematic
141 framework by creating an initial coding scheme for the main themes; and eventually creating an index
142 of themes. In the third stage the thematic framework was applied to all the primary and secondary
143 data in the included papers. A framework matrix was created to arrange the data per the thematic
144 references in the fourth stage. In the fifth and final stage themes were examined for their conceptual
145 similarities and differences (Mapping and interpretation stage). A second reviewer (EL) checked all
146 the themes that were identified and differences in conceptualization were discussed and adjusted.

147

148 **Triangulation of PROMs items with qualitative themes**

149 To examine the extent to which the items within generic and PAD disease specific PROMs
150 corresponded to themes from the qualitative review a triangulation approach was followed (13,14).
151 The items from generic and disease specific PROMs validated in patients with PAD (8) were
152 examined in detail. The items from these instruments were mapped against the themes identified, and
153 two researchers(AA, EL) reviewed both the themes from the qualitative review and the PROM
154 items/domains to evaluate whether the concepts were the same (agreement), offered similar concepts

155 (partial agreement) or were not present (silence). The aim was to identify whether any of the
156 instruments covered all the important issues from the PAD patients' perspective.

157

158 **Results**

159

160 The database searches identified 1113 citations; after removing duplicates, 779 titles were assessed
161 and subsequently 65 full-text papers were reviewed in detail. Finally, only 8 papers fulfilled the
162 inclusion criteria and were included in the qualitative evidence synthesis (**Please see PRISMA chart**
163 **(Figure 1)**). Characteristics and main findings of the studies included in the qualitative synthesis are
164 summarized in table 2.

165

Insert Table 2

166 Two of the studies were conducted in the UK (**15, 16**), three in Sweden (**17-19**) and three in the
167 United States (**20-22**). The studies were published between 1998 and 2015; the mean age of the
168 participants in the included studies ranged from 64-77, and the percentage of male participants was
169 50-79%. The included studies reported the views of 186 patients with PAD including patients with
170 intermittent claudication (IC), critical limb ischaemia (CLI) and amputation of lower limbs due to PAD.

171

172 **Quality assessment**

173 The overall quality of the included studies was good and all the studies scored "yes" for almost all the
174 criteria set in the CASP checklist (**10**); however, four studies scored "can't tell" regarding
175 consideration of the relationship between participants and researcher (**16, 19-21**). Only one study
176 scored 'can't tell' when assessing if the recruitment strategy was appropriate to the aims of the
177 research (**20**). For further detail on the quality of the included studies please see appendix 2.

178 **Analysis**

179 The Framework Analysis of the primary and secondary data in the included papers identified six main
180 issues including symptoms, physical functioning, impact on social functioning, psychological impact,
181 financial impact and process of care. In total thirty-five themes were identified. Table 3 shows the
182 themes and subthemes and the sources from the included papers in this review.

183

Insert Tables 3

184 **Symptoms**

185

186 This theme included several subthemes such as pain, altered sensation, cold extremities, weakness,
187 mobility, ulcers, sexual functioning and symptom progression.

188 **Pain**

189

190 This was identified in all the included papers, severity of the disease resulted in different experiences
191 of pain and this was reflected in the pain subthemes.

192 Patients described different experiences with the initial appearance of the symptoms. Pain was most
193 commonly described as discomfort, ache, cramp and creeping feelings of fatigue that got worse the
194 farther they walked.

195 *“I get a cramping in the left calf.” “My legs get tired. I can feel it in my thighs.” (21)*

196 *“I get this terrible cramp in my legs and then I don’t know where to go.” (17)*

197 The description of pain in the legs and feet was different for patients with CLI. Some of these patients
198 described rest pain and burning sharp pain in their feet and legs. Patients with vascular related
199 amputation described the same type of continuous rest pain prior to their amputation.

200

201 *“If I could, I would have taken an axe and chopped off my leg sooner just to get rid of the pain “*

202 *“When asked, 85% of patients felt that intolerable ischemic rest pain is the most appropriate threshold*
203 *for having their limb amputated, as opposed to ulceration, gangrene, or when their physician stated*
204 *that limb salvage was no longer possible.”*

205 *“I definitely would have had the amputation at the same time point. My pain got so bad, I could not*
206 *walk.” (25)*

207 Rest pain was also reported to be particularly troublesome during the night causing sleep
208 disturbances. Patients had to adapt their position to deal with this pain. Some reported sleeping in a
209 chair to overcome the severity of this pain.

210 *“Experiences such as being forced to sit in a chair during the nights to stand the pain contributed to*
211 *tiredness and feelings of exhaustion.” (17)*

212 *“The greatest benefits of revascularisations were the relief from pain, the ability to sleep again.” (18)*

213

214 Patients with failed revascularisation and subsequent amputation reported pain at the site of
215 amputated limb; however, the phantom pain experienced was tolerable compared to the ischaemic
216 rest pain (22). Furthermore, patients who underwent revascularisation complained of some residual
217 pain following the procedure. Participants in one study reported that they avoided exercise following
218 their intervention and some believed that the pain on walking was an indication that activity causes
219 damage to their muscles and legs (16).

220

221 *Altered Sensation*

222

223 Participants in five studies (15-17, 20, 21) reported altered sensation in the affected limb; these
224 symptoms were experienced by patients prior to and following the procedures. The description of this
225 altered sensation ranged from feeling “a dead weight”, especially in patients with CLI (15), to a minor
226 intermittent tingling feeling in patients with IC (21). Altered sensation secondary to revascularisation
227 was caused by either nerve damage or swelling post interventions (16).

228 *Cold Extremities*

229

230 Patients with chronic severe lower limb ischaemia complained of cold feet and legs; some of these
231 patients reported that despite revascularisation the symptom persisted (18). One participant described
232 this symptom in the following terms:

233 *“I can get up and walk a little and so on. Yes, I have to live with it. It’s sleeping now here and it gets*
234 *cold, like, but when I’m moving the circulation is better. So I see that I’m never going to get rid of it but*
235 *I can live with it because it doesn’t hurt in that way that it did before the operation.” (18)*

236 In one study some participants experienced coldness in the affected limb pre-operatively,
237 postoperatively and after discharge, however, it was worse before revascularisation (15).

238 *Weakness & Fatigue*

239

240 Weakness and fatigue was reported by participants in four studies (16, 17, 19, and 20). Some
241 reported this symptom to be the first they experienced; describing fatigue on walking followed by pain
242 and cramps the more they continued to walk (16, 19). Some experienced loss of power with
243 worsening fatigue as the disease progressed and many complained that despite intervention the

244 fatigue symptoms did not completely resolve. One patient described this this symptom in the following
245 terms:

246 *“Yes, it’s just like it has taken the strength and power from me..” (17)*

247 Many patients described that PAD meant living with long term fatigue and powerlessness **(17, 20)**.

248 *Mobility*

249

250 Mobility problems were found to be the most significant issue for PAD patients in all of the included
251 studies. All the included studies in this review highlighted problems with mobility to be the most
252 important issue experienced by patients with PAD. The impact on mobility differed per the type of
253 symptoms experienced, and the severity of the disease. The impact was worse in patients with CLI
254 and amputees. Patients with IC reported reducing their walking to avoid the symptoms of pain. IC
255 patients also reported employing specific strategies to avoid pain and discomfort on walking by
256 stopping regularly, or avoiding walking uphill or upstairs **(19-21)**.

257

258 *“It depends completely on how hard I walk. If I walk very slowly, I can go many, many blocks, more
259 than a dozen, or so. If I walk aggressively, I can start to feel something in maybe two blocks.” (21)*

260 *“I usually shy away from places where I won’t be able to sit down and rest.” (21)*

261

262 Another patient reported:

263 *“You know hills and stairs; they’re the worst. And carrying things up the stairs is even worse” (19)*

264

265 Patients with CLI felt that their personal independence was compromised due to their problems with
266 mobility. They felt the disease took away their ability to walk completely or reduced their walking
267 ability. This meant for many of them limited daily activities such as housework, shopping and cleaning
268 **(17)**.

269 Many patients used aids such as walking sticks, walking frames and sometimes wheelchairs to
270 overcome issues with mobility; these changes occurred over a long time to adjust to the symptoms
271 **(18)**.

272 Many patients with amputation secondary to PAD reported that problems with mobility had the biggest
273 impact on their quality of life. The major issues with mobility included maintaining their balance,

274 walking upstairs or up ramps. Most patients with amputations relied on using wheelchairs, even if they
275 had prosthesis. Many also reported that they wished that they had met the prosthesis specialists prior
276 to amputation, to prepare them for life after amputation **(22)**.

277 *Non-healing ulcers*

278

279 One of the most distressing symptoms experienced by patients with CLI was non-healing ulcers or
280 wounds. Patients used terms like 'painful' and 'disgusting' to describe their ulcers. Many were
281 concerned about the shape and colour of their leg; the shape of the ulcer had an impact on the type of
282 clothes and shoes they can wear. Several patients also complained of recurrent leg ulcers due to
283 PAD.

284 *"It's troublesome because it runs. That's the hard thing and sometimes it hurts. It's hard to wear*
285 *shoes."* **(17)**

286 *"Well, the district nurse came and looked at it and bandaged it. Then it was all right and then it came*
287 *back, and then it was all right and then it came back again, so it is there now."* **(17)**

288 *Sexual functioning*

289

290 Some patients described a decline in their sexual functioning due to PAD. Although only a minority of
291 patients reported that this was important to their overall quality of life. The decline in sexual function
292 was associated with progression of symptoms of disease **(22)**.

293 *Symptom Progression*

294

295 Participants in four studies understood that PAD is a chronic condition and that it can get worse **(17,**
296 **18 20, 21)**, some reported that they are focusing on avoiding progression of symptoms and worsening
297 of PAD. Many patients' post-intervention adopted new strategies to avoid further intervention by
298 modifying their lifestyle and giving up causative agents such as smoking **(18)**. The perception of the
299 amount of control participants had over their disease progression varied considerably across the
300 studies. These perceptions ranged from having little or none, to having a great deal of control **(20)**.

301 *Impact on Physical Functioning*

302

303 Participants in all the included studies described varying impacts on their ability to care for themselves
304 independently **(15-22)**, participate in exercise or perform their daily activities. The symptoms of pain
305 and reduced mobility had the main impact on physical functioning **(22)**. Patients with severe lower
306 limb ischaemia also suggested that their physical function was affected by a lack of sleep due to their
307 PAD symptoms, in addition to pain at rest or walking. **(20)**.

308 **Impact of PAD on Social Functioning**

309

310 Seven studies described the impact of PAD impact on social life. Many patients reported that their
311 social life was compromised including not being able to maintain their personal role, lack of support
312 from their social circle, isolation and the inability to perform their hobbies. Problems with isolation and
313 lack of social support were worse among patients with amputation secondary to PAD; many of these
314 patients felt that a social support group may improve their quality of life **(22)**. Patients with IC and CLI
315 felt that their symptoms prevented them from keeping their hobbies, visiting family and friends and
316 taking part in many activities that they enjoyed **(15-21)**.

317 **Psychological Impact of PAD**

318

319 The papers reported that patients felt they had no control over their disease. This feeling was more
320 common amongst patients who had revascularisation but still had some residual symptoms, or those
321 that developed complications **(16)**. Many patients suffered from low self-esteem, and felt embarrassed
322 because of their symptoms; for example, some participants described feeling embarrassed because
323 they stopped frequently to ease the pain. Some reported making up excuses to stop, for example
324 pretending to be waiting for someone **(19)**. Patients also suffered with issues of personal image and
325 self-perception, with some patients feeling “old before their time.” **(19)**. Patients also reported the
326 emotional burden of PAD with many experiencing low mood and a sense of loss due to the disease or
327 its complications **(16-21)**. Patients also reported symptoms of anxiety caused by fear of loss of
328 independence, fear of amputation or fear of death **(15-18, 20-22)**.

329 **Financial Impact of PAD**

330

331 One study described the impact of the disease on participants' employment, and their ability to carry
332 out their tasks at work. Many participants in that study thought that these limitations may lead to job

333 loss or the loss of opportunity to be promoted. Some patients planned to change jobs due to their new
334 symptoms. **(20)**.

335 **Process of Care**

336
337

338 All the studies reported that patients had limited understanding about the consequences of surgery.
339 Patients with a diagnosis of IC and no intervention were not clear about their management, and did
340 not understand why they were not offered interventions **(15, 16)**. Many patients did not view walking
341 as therapy for their disease, and therefore avoided walking as they believed the claudication pain was
342 a sign of damage caused to the leg by walking **(16)**.

343 Many patients attempted to change their habits and devised strategies to manage their symptoms;
344 this included alterations in walking by controlling pace, as well as planning stops for longer walks and
345 taking pain relief **(15, 16, 19)**. However, side effects of pain relief medications were a cause for
346 restricted use **(17)**. Some participants wished that their risk factors were modified earlier in the
347 community including help to give up smoking **(20)**.

348 Post-amputation many participants felt that intolerable severe continuous ischaemic rest pain was the
349 most appropriate threshold for amputation and saw no point in the revascularisation attempts at that
350 stage. One patient said:

351 *“Most people would try anything to save the leg.” **(22)***

352 *“I definitely would have had the amputation at the same time point. My pain got so bad, I could not
353 walk.” **(22)***

354 Patients with amputations also reported that meeting with the prosthetics specialists, and spending
355 some time familiarising themselves with the rehabilitation services available, prior to the amputation
356 would have helped their recovery **(22)**.

357

358 Three main subthemes emerged in relation to shared decision making in this review; these were lack
359 of knowledge, expectations and communication barriers.

360 Several patients reported lack of information about the disease and its progress **(16)**. Exercise
361 therapy was recommended for some patients with claudication or post-operatively, however, patients
362 did not understand the importance and relevance of this therapy, and some decided to do the

363 opposite and avoid walking (15, 16, 17). This was mainly because of communication barriers
364 between clinicians and patients.

365 *“When I was in the last time he (surgeon) was talking to a lady doctor and he said I was needing more
366 but he started talking funny words that I did not understand.” (16)*

367

368 *“While I was told I had artery disease, I wasn’t told that I could lose my leg. I would have taken better
369 care of myself.” (22)*

370

371 However, sometime this was because of lack of engagement by the patients and handing control over
372 decision-making to the clinicians.

373 *“The likes of [surgeons], they know what they are talking about, they don’t say things unless they are
374 sure so I accept what they want to do.” (15)*

375

376 Patient expectation was also a significant issue. Some had no knowledge of the overall impact of the
377 atherosclerosis on their health generally, and others expected the intervention to fully cure the
378 disease. Although most patients reported satisfaction with their intervention some were disappointed
379 with the results post-operatively as they expected to be back to their pre-disease state with no
380 symptoms or disability (15-16, 18, 22).

381 **Triangulation**

382 The identified themes were compared to items from validated PROMs that were identified in a recent
383 study (8). These PROMs include peripheral artery disease quality of life questionnaire (PADQOL),
384 vascular quality of life questionnaire (VascuQoL), Australian vascular quality of life index
385 (AUSVIQUOL), peripheral artery questionnaire (PAQ), Intermittent claudication questionnaire (ICQ),
386 walking impairment questionnaire (WIQ), EuroQoL-5D (EQ-5D-3L), Nottingham health profile (NHP)
387 and Medical outcomes study 36-item short form (SF-36 ®). Two reviewers examined the overlap
388 between the themes in the qualitative review and items in the validated PROMs; when there was
389 complete overlap between the theme and an item in a PROMs an agreement score (+) was awarded;
390 however, when the theme is covered in a general question a partial agreement score was awarded
391 (+/-). For instance, EQ-5D has a domain about pain, this domain overlaps completely (is in agreement
392 (+)) with the pain theme; the same domain overlaps with themes such as pain on walking, rest pain,

393 night pain and phantom pain; although this domain in EQ-5D-3L does not ask about them specifically.
394 When the theme is not covered at all a silence score (-) was awarded; for example, in EQ-5D-3L there
395 is no questions about sexual functioning or altered sensation.

396 The best generic PROMs that captured all the important issues for patients with PAD was the NHP
397 and the disease specific PROMs with the best fit with the themes from the qualitative review was the
398 VascuQoL. However, VascuQoL did not cover issues important to patients who had an amputation
399 secondary to PAD.

400 WIQ only covered important symptoms, whereas ICQ only covered some of the themes important to
401 patients with intermittent claudication. For further details on the results of triangulation see table 4.

402 [Insert Tables 4](#)

403

404 Discussion

405

406 We identified thirty-five themes associated with quality of life for those with different forms of PAD.

407 These themes were divided into six groups: symptoms, physical functioning, impact on social
408 functioning, psychological impact, financial impact and process of care

409 Measuring quality of life for people with PAD including patients with IC, CLI and amputation is of
410 interest currently because of the introduction of new treatment modalities such as drug eluting stents
411 and drug coated balloon angioplasty, as well as emerging evidence from trials comparing bypass
412 operation to endovascular therapies. Outcome measures, such as limb salvage, patient survival,
413 patency of bypass or vascularised artery, and re-intervention rates, have been used to compare
414 outcomes between therapies for patients with PAD, and to inform decision making for patients with
415 PAD. However, quality of life and functional status is what matters the most to patients **(23, 24)**.

416

417 One of the strengths of this study is that the qualitative review included studies of patients with
418 different manifestations of PAD, as PAD can present with a spectrum of symptoms, and with varying
419 severity. The inclusion in the review of patients with IC, CLI and amputation ensured that the variation
420 of impacts on QoL were captured. This is important due to the complexity of PAD presentation, since
421 patients could have IC or CLI or had an amputation in one leg and suffer from a different stage of the
422 disease in the other leg. Validated PROMs in this field cover only a stage of the disease. A

423 comprehensive measure can be used to examine the outcomes of patients at different stages of the
424 disease.

425

426 This review incorporated evidence from a previous systematic review **(8)** also conducted by the same
427 research team, which identified PROMs validated for use with patients with PAD. In the triangulation
428 section of this study the themes from this qualitative review were mapped against the domains from
429 the validated generic and disease specific PAD PROMs that were identified in the separate review.

430

431 The main limitations of this study are that some of the included papers in the qualitative review did not
432 specify the severity of PAD in the patients included. In other studies, the investigators reported the
433 severity but did not distinguish between the themes based on the type of PAD. Furthermore, there
434 was only one study that reported on the quality of life of patients with PAD related amputation.

435

436 The review identified the important symptoms from the patients' perspective, these included pain,
437 altered sensation, cold extremities, fatigue/weakness, issues of mobility, ulcers, sexual functioning
438 and symptom progression. This study also revealed that patients with critical ischaemia and
439 intermittent claudication post-intervention complained from some of these symptoms with varying
440 degree. Furthermore, many patients with critical ischaemia expressed their views that quality of life
441 and severity of symptoms should be considered when deciding the timing and type of intervention
442 whether that is revascularisation or amputation.

443

444 Amongst some academic and clinical circles quality of life has confusingly come to be known as
445 anything which is not clinical **(25)**. However, this review indicates that, when patients with PAD are
446 asked, the distress related to symptoms is integral to their quality of life, and in some instances seeing
447 beyond the distress of pain and lack of mobility is difficult. The type of pain, its onset, as well as
448 location, was different depending on the severity of disease; the same applied to fatigue, weakness,
449 altered sensation and mobility. Mobility issues were different between a patient post amputation, and
450 someone with claudication; however, the issue remained relevant to both groups.

451

452 Issues relating to impact on psychological wellbeing included the following subthemes: lack of control
453 over life, negative impact on self-esteem, self- perception, impact on mood, fear of amputation, loss of
454 independence and death. The impact of these problems differed between patients depending on the
455 whether they suffered with claudication symptoms only, if they had severe ischaemia, or if they had
456 undergone an amputation.

457

458 One of the strongest finding of this study is that when the themes generated from the review were
459 mapped against the generic and disease specific PROMs validated in patients with PAD, none of
460 them covered all the important issues revealed by the review. This is likely because the review
461 included studies that interviewed patients with IC, CLI and PAD related amputations; therefore
462 including all the themes important to patients with symptomatic PAD. This provides important
463 evidence for critically examining the content of PROMs currently being used in patients with PAD and
464 particularly the generic measures such as EQ-5D-3L and SF-36.

465

466 Both PROMs are used commonly to inform resource allocation decisions as well monitoring quality of
467 life. There are several concerns with generic PROMS for instance EQ-5D-3L & SF-36 were designed
468 by experts with no input from patients with PAD and their coverage does not include all the important
469 issues to patients with IC, CLI and amputation secondary to PAD. The EQ-5D-3L has five dimensions
470 of health: mobility, self-care, usual activities, pain and discomfort, and depression and anxiety.

471 Respondents are asked to report their level of problems (no problems, slight/moderate problems or
472 severe/extreme problem) on each dimension to provide an overall score for the health state. A key
473 concern raised about this measure is the focus on physical health with little focus of psychological
474 wellbeing.

475

476 The findings of this study can help to provide useful evidence for examining the content validity of
477 different measures. This evidence can be used alongside quantitative psychometric evidence to
478 design a new disease specific measure. Our group designed this instrument and aim to perform factor
479 analysis and well as further psychometric analysis in a large survey of patients with PAD.

480

481

482 **“Data Availability Statement”**

483 The analysis data cannot be shared since some of the papers included in the systematic review have
484 copy rights and these prohibit publishing them in other journals but allow researchers to use them for
485 secondary analysis. These papers were uploaded into the software in which we performed the
486 analysis. Supplementary materials are included regarding the search strategy and analysis.

487 **Compliance with Ethical Standards**

488 **Acknowledgment**

489 Ahmed Aber contributed to the analysis and interpretation of data, drafting of the manuscript, and
490 critical revision; Elizabeth Lumley contributed to the analysis and interpretation of data and drafting of
491 the manuscript; Patrick Phillips contributed to reviewing the data as well as the analysis and the
492 manuscript drafting; Helen Buckley Woods performed the searches for the systematic review and
493 helped in drafting of the manuscript. Georgina Jones contributed to the study conception and design,
494 analysis and interpretation of data, and drafting of the manuscript; and Jonathan Michaels contributed
495 to the study conception and design, drafting of the manuscript, and critical revision.

496

497 **Funding**

498 This study was funded by the United Kingdom National Institute for Health Research (NIHR) under
499 the Programme Grants for Applied Research programme (RP-PG-1210-12009). The views expressed
500 are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

501 **Conflict of interest**

502

503 Ahmed Aber, Elizabeth Lumley, Patrick Phillips, Helen Buckley Woods, Georgina Jones, Jonathan
504 Michaels have no conflicts of interest directly relevant to the content of this article.

505

506

507

508

509

510

511

512

- 514 1- Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery
515 Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general
516 population. *International Journal of Epidemiology*. 1991; 20(2):384-392
- 517 2- Kannel WB, Skinner JJ, Jr., Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the
518 Framingham Study. *Circulation*. 1970; 41(5):875-883
- 519 3- American Diabetes Association. Peripheral arterial disease in people with diabetes. *Diabetes Care*.
520 2003; 26(12):3333-3341
- 521 4- Leng GC, Lee A, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, natural history and
522 cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general
523 population. *International Journal of Epidemiology*. 1996; 25(6):1172-1181
- 524 5- Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005
525 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity,
526 renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for
527 Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and
528 Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the
529 ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the
530 Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of
531 Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for
532 Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.
533 *Circulation*. 2006; 113(11):e463-e654
- 534 6- Park KB, Do YS, Kim DI, Kim DK, Kim YW, Shin SW et al. The TransAtlantic InterSociety
535 Consensus (TASC) classification system in iliac arterial stent placement: long-term patency and
536 clinical limitations. *Journal of Vascular & Interventional Radiology*. 2007; 18(2):193-201
- 537 7- Department of Health. Liberating the NHS: Transparency in outcomes- a framework for the NHS. July
538 2010. <http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=1280> (Accessed 08 June
539 2017)
- 540 8- Poku E, Duncan R, Keetharuth A, Essat M, Phillips P, Woods HB, Palfreyman S, Jones G, Kaltenthaler
541 E & Michaels J (2016) Patient-reported outcome measures in patients with peripheral arterial disease: a
542 systematic review of psychometric properties. *Health Qual Life Outcomes*, 14(1), 161-161.
- 543 9- Duncan R, Booth A, Woods HB, Essat M, Phillips P, Poku, E, Kaltenthaler E, Jones G, Michaels J.
544 Understanding the experience and impact of living with a vascular condition from the patients'
545 perspective: qualitative evidence synthesis protocol. HEDS discussion paper. May 2016.
546 https://www.sheffield.ac.uk/polopoly_fs/1.552397!/file/DP_16_05.pdf (Accessed 08 June 2017)
- 547 10- CASP. 10 Questions To Help You Make Sense of Qualitative Research. CASP Qual Checkl [Internet].
548 2006;1–6. Available from:
549 http://media.wix.com/ugd/dded87_951541699e9edc71ce66c9bac4734c69.pdf
- 550 11- Carroll C, Booth A. Quality assessment of qualitative evidence for systematic review and synthesis: Is
551 it meaningful, and if so, how should it be performed? *Res Synth Methods* [Internet]. 2014;(August):
552 Available from: <http://doi.wiley.com/10.1002/jrsm.1128>
- 553 12- Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In *Analysing Qualitative*
554 *Data*, Bryman G, Burgess A (eds). Routledge: London, 1994; 173–194.
- 555 13- Farmer T, Robinson K, Elliott SJ, Eyles J. Developing and implementing a triangulation protocol for
556 qualitative health research. *Qual Health Res* 2006; 16: 377–394.
- 557 14- O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods
558 studies. *BMJ* 2010; 341: c4587.
- 559 15- Gibson JM, Kenrick M. Pain and powerlessness: the experience of living with peripheral vascular
560 disease. *Journal of Advanced Nursing*. 1998, 27:737-745
- 561 16- Cunningham M, Swanson V, Pappas E, O'Carroll R, Holdsworth RJ. Illness beliefs and walking
562 behaviour after revascularisation for intermittent claudication - a qualitative study. *J Cardiopulm*
563 *Rehabil Prev*. 2014; 34(3):195-201
- 564 17- Wann-Hansson C, Hallberg IR, Klevsgard R, Andersson E. Patients' experiences of living with
565 peripheral arterial disease awaiting intervention: a qualitative study. *International Journal of Nursing of*
566 *Studies*. 2005;42:851-862
- 567 18- Wann-Hansson C, Hallberg IR, Klevsgard R, Andersson E. The long-term experience of living with
568 peripheral arterial disease and the recovery following revascularisation: A qualitative study.
569 *International Journal of Nursing of Studies*. 2008; 45:552-561
- 570 19- Eberg L, Andreassen S, Mattiasson AC. Experiences of living with intermittent claudication. *Journal of*
571 *Vascular Nursing*. 2012; 30(1):5-10

- 572 20- Treat-Jacobson D, Halverson SL, Ratchford A, Regensteiner JG, Lindquist R, Hirsch AT. A Patient-
573 derived Perspective of Health-related Quality of Life With Peripheral Arterial Disease. *Journal of*
574 *Nursing Scholarship*. 2002; 34(1):55-60
- 575 21- Schorr EN, Peden-McAlpine C, Treat-Jacobson D, Lindquist R.Characterization of
576 the peripheral artery disease symptom experience. *Geriatric Nursing*. 2015; 36(4):293-300
- 577 22- Suckow BD, Goodney PP, Nolan BW, Veeraswamy RK, Gallagher P, Cronenwett JL, Kraiss LW.
578 Domains that Determine Quality of Life in Vascular Amputees. *Annals of Vascular of Surgery*. 2015;
579 29(4):722-30
- 580 23- Abou-Zamzam AM, Lee RW, Moneta GL, et al. Functional outcome after infrainguinal bypass for
581 limb salvage. *J Vasc Surg*. 1997;25:287-97.
- 582 24- Gulati S, Coughlin PA, Hatfield J, et al. Quality of life in patients with lower limb ischemia; revised
583 suggestions for analysis. *J Vasc Surg*. 2009;49:122-6.
- 584 25- Bowling A: *Measuring Health. A review of quality of life measurement scales*. Buckingham: Open
585 University Press; 1997.
- 586
587
588